XML 18 R7.htm IDEA: XBRL DOCUMENT

Organization and Description of the Business	3 Months Ended
Organization and Description of the Business	Mar. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Description of the Business	Organization and Description of the Business Trevena, Inc., or the Company, was incorporated in Delaware as Parallax Therapeutics, Inc. on November 9, 2007. The Company began operations in December 2007, and its name was changed to Trevena, Inc. on January 3, 2008. The Company is a biopharmaceutical company developing innovative therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. The Company operates in one segment and has its principal office in King of Prussia, Pennsylvania. Liquidity At March 31, 2017, the Company had an accumulated deficit of $306.3 million. The Company’s net loss was $20.7 million and $17.8 million for the three months ended March 31, 2017 and 2016, respectively. The Company expects its cash and cash equivalents of $18.7 million and marketable securities of $79.3 million as of March 31, 2017, together with interest thereon, to be sufficient to fund its operating expenses and capital expenditure requirements into the third quarter of 2018.